Bernard Doger

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

David M. Hyman, Sarina A. Piha‐Paul, Helen Won et al. · Nature · 2018 · 752 citations · Full text

Tumor Biology, Oncology, Medicine +8

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Elena Garralda, Marie-Ève Beaulieu, Víctor Moreno et al. · Nature Medicine · 2024 · 145 citations · Full text

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

Matt D. Galsky, Gianluca Del Conte, Silvia Foti et al. · Journal of Clinical Oncology · 2022 · 85 citations

Immunology, Immunoediting, Pathology +17

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo et al. · European Journal of Cancer · 2017 · 75 citations

Lymphoid Neoplasia, Medicine, Malignant Blood Disorder +8

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Víctor Moreno, María Vieito, Tatiana Hernández‐Guerrero et al. · Annals of Oncology · 2020 · 66 citations · Full text